EQ vs ARAY Comparison

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.